CD19 and acute lymphoblastic leukemia: Clinical trials have demonstrated that anti-CD19 CAR-T cells with entirely human binding domains are capable of mediating durable disease remission with a long-lasting existence in both children and young adults with relapsed or refractory (R/R) B-acute lymphoblastic leukemia (B-ALL), even in patients who have previously received prior but unsuccessful CAR-T cell therapy [96,97,98].